A prospective, multicenter study found that a blood-based miRNA assay combined with CA19-9 improved early detection of pancreatic ductal adenocarcinoma.
News|Articles|August 1, 2008
August 2008 Oncology News International
Advertisement
Cover Story
- High cost of biologics takes a toll on hem/onc practices
- FDA cracks down on counterfeit cancer cure products
DEPARTMENTS
Focus on Breast Cancer
- Mastectomy rates for early breast cancer are on the upswing at one Mayo Clinic
- Is breast MRI primed for widespread use as a high-risk screening tool?
- Vantage Point: Risk factors will guide the imaging paradigm
Focus on Lung Cancer
- Anti-IGF-1R antibody plus chemo active in advanced non-small-cell lung cancer
News & Analysis
- Oncologic drug safety: Separating fact from fiction
Focus on Prostate Cancer
- Dual antiangiogenic therapy plus chemo is active in advanced prostate cancer
Advertisement
Related to this article
Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma.
The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
Using Intrathecal Dendritic Cells for Leptomeningeal Disease From Breast Cancer
5